

Special Issue

Diagnostic and Therapeutic Advances in Retinal Disease

Message from the Guest Editors

Degenerative diseases of the retina continue to be a leading cause of vision loss. Further advances in the treatment of retinal degeneration will require a deeper understanding of the molecular pathophysiology of these diseases. This Special Issue will promote this goal by highlighting notable advances in the diagnosis and therapy of retinal degenerative (RD) disease. In the area of retinal disease diagnosis, contributions are invited that feature innovations and advances in such areas as molecular diagnostics, imaging, applications of artificial intelligence or informatics to assist in complex diagnoses, and innovative approaches that are based on multifactorial diagnostic indicators. Gene therapies, neuroprotection, in vivo gene editing, retinal replacement, regeneration, immunomodulation, and therapeutic monoclonal antibody modalities to managing the RD diseases are all welcome in this Special Issue.

- Cell therapy
- Gene therapy
- Neuroprotection
- Regeneration
- Retinal ganglion cells
- Retinal pigment epithelium
- Therapeutic antibodies
- Vision restoration

Guest Editors

Prof. Dr. Randolph D. Glickman

Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Dr. Igor O. Nasonkin

Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Deadline for manuscript submissions

7 August 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/84471

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).